Literature DB >> 24293346

Novel therapies for treating familial hypercholesterolemia.

Salman J Bandeali1, Jad Daye, Salim S Virani.   

Abstract

Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting different cholesterol pathways. This article briefly summarizes familial hypercholesterolemia and then discusses the newer pharmacotherapies available in the management of familial hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24293346     DOI: 10.1007/s11883-013-0382-0

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  47 in total

Review 1.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 2.  Efficacy criteria and cholesterol targets for LDL apheresis.

Authors:  Gilbert R Thompson; M Barbir; D Davies; P Dobral; M Gesinde; M Livingston; P Mandry; A D Marais; S Matthews; C Neuwirth; A Pottle; C le Roux; D Scullard; C Tyler; S Watkins
Journal:  Atherosclerosis       Date:  2009-06-18       Impact factor: 5.162

3.  Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.

Authors:  Robert J Smith; William R Hiatt
Journal:  JAMA Intern Med       Date:  2013-09-09       Impact factor: 21.873

4.  Novel therapies and new targets of treatment for familial hypercholesterolemia.

Authors:  Anne Carol Goldberg
Journal:  J Clin Lipidol       Date:  2010-08-21       Impact factor: 4.766

5.  Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.

Authors:  Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2007-01-22       Impact factor: 5.922

6.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

Authors:  Evan A Stein; Dan Gipe; Jean Bergeron; Daniel Gaudet; Robert Weiss; Robert Dufour; Richard Wu; Robert Pordy
Journal:  Lancet       Date:  2012-05-26       Impact factor: 79.321

7.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

8.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

9.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

10.  Familial hypercholesterolemia and the atherosclerotic disease.

Authors:  Yoo Ri Kim; Ki Hoon Han
Journal:  Korean Circ J       Date:  2013-06       Impact factor: 3.243

View more
  2 in total

Review 1.  Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway.

Authors:  Annalisa Marcuzzi; Elisa Piscianz; Claudia Loganes; Liza Vecchi Brumatti; Alessandra Knowles; Sabrine Bilel; Alberto Tommasini; Roberta Bortul; Marina Zweyer
Journal:  Int J Mol Sci       Date:  2015-12-30       Impact factor: 5.923

Review 2.  Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.

Authors:  Xiaoming Jia; Mahmoud Al Rifai; Jing Liu; Anandita Agarwala; Martha Gulati; Salim S Virani
Journal:  Curr Atheroscler Rep       Date:  2020-06-18       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.